Since the virus can't gain a foothold on cells that lack CCR5, people who have the mutation have natural protection.

如果细胞上没有足够的CCR 5, HIV病毒就无法在细胞上立足，所以有发生这种突变的人自然可以受到保护。

youdao

One big question: would the limited data Sarepta has so far collected from a very small clinical trial of its drug eteplirsen, a treatment for Duchenne muscular dystrophy that is caused by a very specific type of mutation, be enough to warrant filing with the Food and Drug Administration and perhaps even gain approval?

FORBES: A Key Exchange On Sarepta Therapeutics' Promising Muscular Dystrophy Drug